0001225208-18-010754.txt : 20180619 0001225208-18-010754.hdr.sgml : 20180619 20180619105521 ACCESSION NUMBER: 0001225208-18-010754 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180618 FILED AS OF DATE: 20180619 DATE AS OF CHANGE: 20180619 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Schechter Adam H CENTRAL INDEX KEY: 0001376841 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-06571 FILM NUMBER: 18906474 MAIL ADDRESS: STREET 1: 2000 GALLOPING HILL ROAD CITY: KENILWORTH STATE: NJ ZIP: 07033 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Merck & Co., Inc. CENTRAL INDEX KEY: 0000310158 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 221918501 STATE OF INCORPORATION: NJ FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2000 GALLOPING HILL ROAD CITY: KENILWORTH STATE: NJ ZIP: 07033 BUSINESS PHONE: 908-740-4000 MAIL ADDRESS: STREET 1: 2000 GALLOPING HILL ROAD CITY: KENILWORTH STATE: NJ ZIP: 07033 FORMER COMPANY: FORMER CONFORMED NAME: Merck & Co. Inc. DATE OF NAME CHANGE: 20091103 FORMER COMPANY: FORMER CONFORMED NAME: SCHERING PLOUGH CORP DATE OF NAME CHANGE: 19920703 4 1 doc4.xml X0306 4 2018-06-18 0000310158 Merck & Co., Inc. MRK 0001376841 Schechter Adam H MERCK & CO., INC. 2000 GALLOPING HILL ROAD KENILWORTH NJ 07033 1 EVP & Pres-Global Human Health Common Stock 2018-06-18 4 M 0 100000.0000 36.5600 A 100000.0000 D Common Stock 2018-06-18 4 S 0 100000.0000 61.0016 D 0.0000 D Common Stock 2018-06-18 4 S 0 34094.0000 61.0015 D 62765.9747 I By Trust Stock Option (right to buy) 36.5600 2018-06-18 4 M 0 100000.0000 0.0000 D 2012-05-04 2021-05-03 Common Stock 100000.0000 100000.0000 D The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.5900 to $61.3200, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. The sale reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.6100 to $61.3100, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote. Holdings include shares acquired in dividend reinvestment transactions. The option became exercisable in equal installments on 5/4/2012, 5/4/2013 and 5/4/2014. Faye C. Brown as Attorney-in-Fact for Adam H. Schechter 2018-06-19